Next Generation of Preclinical Liver Cancer Models

Clin Cancer Res. 2015 Oct 1;21(19):4254-6. doi: 10.1158/1078-0432.CCR-15-1152. Epub 2015 Jul 13.

Abstract

Because of its heterogeneity, lack of prognostic markers, tumor-escape mechanisms, and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and colleagues characterize a rodent model that might help identify novel drugs for combinatorial sorafenib-based therapies for HCC.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / mortality
  • Comparative Genomic Hybridization
  • Disease Models, Animal
  • Genetic Heterogeneity
  • Humans
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics
  • Liver Neoplasms / mortality
  • Magnetic Resonance Imaging
  • Molecular Targeted Therapy
  • Niacinamide / analogs & derivatives
  • Niacinamide / pharmacology
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / pharmacology
  • Phenylurea Compounds / therapeutic use
  • Positron-Emission Tomography
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Sorafenib

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Niacinamide
  • Sorafenib